In vitro effects of inogatran. A selective low molecular weight thrombin inhibitor

Thrombosis Research

Volumn 85, Issue 2, 1997, Pages 133-145

  Teger Nilsson, Ann Catrine ^a   Bylund, Ruth ^a   Gustafsson, David ^a   Gyzander, Erika ^a   Eriksson, Ulf ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

anticoagulant; dipeptide; inogatran; selectivity; thrombin; thrombin inhibitor

Indexed keywords

INOGATRAN; THROMBIN INHIBITOR;

ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DOG; HUMAN; NONHUMAN; PLASMA; PRIORITY JOURNAL; RAT; THROMBOSIS;

ADENOSINE DIPHOSPHATE; ANIMALS; ANTITHROMBINS; COLLAGEN; DOGS; FIBRINOLYSIS; GLYCINE; HUMANS; KINETICS; MALE; PIPERIDINES; PLATELET AGGREGATION; RATS; RATS, SPRAGUE-DAWLEY; SERINE ENDOPEPTIDASES; THROMBIN; THROMBIN TIME;

EID: 0030932442     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(96)00230-7     Document Type: Article

References (24)

1. MARKWARDT, F. Die Isoliering und chemische Charakterisierung des Hirudins. Hoppe Seylers Z Physiol Chem 308, 147-156, 1957.
2. PETERSEN, T.E., ROBBERTS, H.R., SOTRUP-JANSEN, L. and MAGNUSSON, S. Primary structure of hirudin, a thrombin-specific inhibitor. In: Protides of the Biologic Fluids. H. Paeters (ed.), pp 145-149, Pergamon Press, Oxford, 1976. .
3. MARKWARDT, F. The development of hirudin as an antithrombotic drug. Thromb Res 74, no 1, 1-23, 1994.
4. OKAMOTO, S., WANAKA, K., and HIJIKATA-OKUNOMIYA, A. In vitro and in vivo properties of synthetic inhibitors of thrombin: Recent advances. Adv Exp Med Biol 340, 119-130, 1993.
5. BUSH, L.R. Argatroban, a selective, potent thrombin inhibitor. Cardiovasc Drug Rev 9, 247-263, 1991.
6. MARKWARDT, F. and HAUPTMANN, J. Synthetic thrombin inhibitors as anticoagulants pharmacological aspects. Adv Exp Med Biol 340, 143-171, 1993.
7. HILPERT, K., ACKERMANN, J., BANNER, D.W., GAST, A., GUBERNATOR, K., HADVARY, P., LABLER, L., MÜLLER, K., SCHMID, G., TSCHOPP, T.B. and VAN DE WATERBEEMD, H. Design and synthesis of potent and highly selective thrombin inhibitors. J Med Chem 37, 3889-3901, 1994.
8. BLOMBÄCK, B., BLOMBÄCK, M., OLSSON, P., SVENDSEN, L. and ÅBERG, G. Synthetic peptides with anticoagulant and vasodilating activity. Scand J Clin Lab Invest 24, (Suppl. 107), 59-66, 1969.
9. 2Cl - a selective affinity label for thrombin. Thromb Res 14, 969-973, 1979.
10. BAJUSZ, S., SZELL, E., BAGDY, D. BARABAS, E., HORVATH, G., DIOSZEGI, M., FITTLER, Z., SZABO, G., JUHASZ, A., TOMORI, E. and SZILAGYI, G. Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation and its stable N-methyl derivative, D-MePhe-Pro-Arg-H. J Med Chem 33, 1729-1735, 1990.
11. KETTNER, C., MERSINGER, L. and KNABB, R. The selective inhibition of thrombin by peptides of boroarginine. J Biol Chem 265, 18289-19297, 1990
12. JONES, D.M., ATRASH, B., RYDER, H., TEGER-NILSSON, A.-C., GYZANDER, E. and SZELKE, M. Thrombin inhibitors based on ketone derivatives of arginine and lysine. J Enzyme Inhibition 9, 43-60, 1995.
13. MARAGANORE, J.M., BOURDON, P., JABLONSKI, J., RAMACHANDRAN, K.L. and FENTON, J.W. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29, 7095-7101, 1990.
14. TEGER-NILSSON, A.-C. and BYLUND R. Preparation of peptide derivatives as thrombin inhibitors. PCT Int Appl, WO 9311152, Al; 930610.
15. STONE, S.R. and HOFSTEENGE, J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 25, 4622-4628, 1986.
16. TEGER-NILSSON, A.-C., ERIKSSON, U., GUSTAFSSON, D., BYLUND, R., FAGER, G. and HELD, P. Phase I studies on inogatran, a new selective thrombin inhibitor. J Am Coll Cardiol, Special issue. Abstract from ACC Meeting, New Orleans, March 1995, p 117A, 1995.
17. HEMKER, H.C. Thrombin generation, an essential step in haemostasis and thrombosis. In: Haemostasis and Thrombosis. Bloom, A.L., Forbes, C.D., Thomas, D.P. and Tuddenham, E.G.D. (eds.), pp 477-490, Churchill Livingstone, Edinburgh (1994)..
18. GUSTAFSSON, D., ELG, M., LENFORS, S., BÖRJESSON, I. and TEGER-NILSSON, A.-C. Effects of inogatran, a new low molecular weight thrombin inhibitor, on rat models of thrombosis. Thromb Haemostas 73, 1319, 1995. Abstract from ISTH-Meeting, Jerusalem, June 1995.
19. HAUPTMANN, J., KAISER, B., NOWAK, G., STURZEBECHER, J., MARKWARDT, F. Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors. Thromb. Haemostas, 73, 220, 1990.
20. ERIKSSON, U.G., RENBERG, L., VEDIN C. and STRIMFORS, M. Pharmacokinetics of inogatran, a new low molecular weight thrombin inhibitor, in rats and dogs. Abstract from ISTH-Meeting, Jerusalem, June 1995.
21. GUSTAFSSON, D., ELG, M., LENFORS, S., BÖRJESSON, I. and TEGER-NILSSON, A.-C. Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. Blood Coag Fibrinol 7, 69-79, 1996
22. CHEN, L., NICHOLS, W.W., MATTSSON, C., TEGER-NILSSON, A.-C., SALDEEN, T. and MEHTA, J.L. Inogatran, a novel direct low molecular weight thrombin inhibitor given with, but not after, tissue-plasminogen activator improves thrombolysis. J Pharmacol Exp Ther 32, 1276, 1996.
23. CHEN, L.Y., NICHOLS, W.W., MATTSSON, C., TEGER-NILSSON, A.-C., WALLIN, R., SALDEEN, T. and MEHTA, J.L. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during thrombolysis. Cardiovasc Res 30, 866-874, 1995.
24. URIUDA, Y., WANG, Q.-D., RYDÉN, L., GRIP, L., SJÖQUIST, P.-O. and MATTSSON, C. Anti-thrombotic activity of inogatran, a new low-molecular weight-inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis. Cardiovasc Res 32, 320. 1996.